Company news
PepGen Inc. news in 2024
PepGen Inc.'s news releases, calls and decks from 2024, newest first.
PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy
December 15, 2024
PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development
November 20, 2024
PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
November 6, 2024
PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society
October 7, 2024
PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors
September 18, 2024
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Vice President, Research & Development
August 19, 2024
PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development
August 19, 2024
PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
August 7, 2024
PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy
July 29, 2024
PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications
July 1, 2024
PepGen Announces Executive Team Promotions
June 10, 2024
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 13, 2024
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
March 12, 2024
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
March 5, 2024
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
March 3, 2024
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1
February 19, 2024
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock
February 6, 2024
Mary Beth DeLena Joins PepGen as General Counsel and Secretary
January 16, 2024
PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping
January 7, 2024
Decks in 2024
- Technical Presentation (July 2024)
Technical · 34 slides · Jul 30, 2024
- Technical Presentation (2024)
Technical · 9 slides · 2024